| [1] |
Adam R, De Gramont A, Figueras J , et al. Jean-Nicolas Vauthey of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus[J]. Oncologist, 2012,17:1225-1239 .
|
| [2] |
Tellez C, Benson AB 3rd, Lyster MT , et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature[J]. Cancer, 1998,82:1250-1259.
|
| [3] |
Levy J, Zuckerman J, Garfinkle R , et al. Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a systematicreview and meta-analysis[J]. HPB (Oxford), 2018,20:905-915
|
| [4] |
Martin RC, Joshi J, Robbins K , et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study[J]. Ann Surg Oncol, 2011,18:192-198.
|
| [5] |
Hong K, McBride JD, Georgiades CS, et al. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization[J]. J Vasc Interv Radiol, 2009,20:360-367.
|
| [6] |
Zhang H, Guo J, Gao S , et al. Prognostic factors for transarterial chemoembolization combined with sustained oxaliplatin-based hepatic arterial infusion chemotherapy of colorectal cancer liver metastasis[J]. Chin J Cancer Res, 2017,29:36-44.
|
| [7] |
Van Cutsem E. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J]. Ann Oncol, 2016, Aug; 27(8):1386-422.
|
| [8] |
Hayashi M1, Inoue Y, Komeda K , et al. Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis[J]. BMC Surg, 2010, Sep 27; 10:27.
|
| [9] |
Kemeny N . Management of liver metastases from colorectal cancer[J]. Oncology (WillistonPark), 2006,20:1161-1176,1179.
|
| [10] |
Nancy E. Kemeny, William R , et al. Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Chemotherapy With or Without Bevacizumab in Patients With Resected Hepatic Metastases From Colorectal Cancer[J]. J Clin Oncol, 2011,29:884-889.
|
| [11] |
Dell'Aquila E, Cremolini C. Prognostic and edictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO[J]. Ann Oncol. 2018, Apr 1; 29(4):924-930.
|
| [12] |
Folprecht G1, Gruenberger T. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)[J]. Ann Oncol, 2014, May; 25(5):1018-25.
|
| [13] |
Kemeny NE, Melendez FD, Capanu M , et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma[J]. J Clin Oncol, 2009,27(21):3465-3471.
|
| [14] |
Hoffmann RT, Paprottka P, Jakobs TF , et al. Arterial therapies of colorectal cancer metastases to the liver[J]. Abdom Imaging, 2011,36(6):661-670.
|
| [15] |
Kemeny MM, Adak S, Gray B , et al. Combinedmodality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—An intergroup study[J]. J Clin Oncol, 2002,20:1499-1505.
|
| [16] |
Levy J, Zuckerman J, Garfinkle R , et al. Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a systematic review and meta-analysis[J]. HPB (Oxford), 2018,20:905-915
|
